Ikarian Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ikarian Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-160,200	Closed	-$1.77M	–	177
2023 Q2	$1.77M	Buy	160,200 +75,000	+88%	+$1.04M	0.28%	67
2023 Q1	$1.14M	Hold	85,200	–	–	0.26%	71
2022 Q4	$1.05M	Hold	85,200	–	–	0.25%	49
2022 Q3	$1.19M	Sell	85,200 -19,800	-19%	-$319K	0.24%	65
2022 Q2	$1.45M	Buy	105,000 +69,851	+199%	+$1.12M	0.26%	67
2022 Q1	$572K	Buy	35,149 +584	+2%	+$9.15K	0.08%	128
2021 Q4	$562K	Hold	34,565	–	–	0.08%	122
2021 Q3	$513K	Sell	34,565 -435	-1%	-$6.96K	0.04%	187
2021 Q2	$700K	Hold	35,000	–	–	0.06%	173
2021 Q1	$808K	Buy	+35,000	New	+$976K	0.03%	243

Other funds holding ICPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Ikarian Capital's ICPT Position: Q3 2023 in Review

Ikarian Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 160,200 shares — an estimated $1.77M sold.

Ikarian Capital first reported a position in ICPT in Q1 2021 and held it in 10 quarters. The position peaked at $1.77M in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

Ikarian Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 160,200 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.77M.
Ikarian Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2021 and held it in 10 quarters.
Ikarian Capital's Intercept Pharmaceuticals, Inc. position peaked at $1.77M in Q2 2023.
146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.